EGFR-targeted therapy for patients with colorectal cancer: patient management and future directions.
The epidermal growth factor receptor (EGFR) signaling pathway is of particular relevance for patients with colorectal cancer (CRC); preclinical data indicate a role for EGFR in tumor cell growth, invasion, metastasis, and tumor angiogenesis. The goal of this program is to provide an overview of the EGFR signaling pathway as well as current and future treatment options for EGFR-targeted therapy in patients with CRC.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000401:mortality / Q000628:therapy*; D003875:Drug Eruptions / Q000145:classification / Q000209:etiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000502:physiology; D005544:Forecasting; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000502:physiology; D006801:Humans; D024802:Nurse's Role; D009859:Oncology Nursing / Q000379:methods; D012720:Severity of Illness Index; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D000970:Antineoplastic Agents; D066246:ErbB Receptors